title: Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus.
abstract: As the modern era of combination antiretroviral therapy has increased life expectancy for individuals infected with the human immunodeficiency virus (HIV), type 2 diabetes mellitus and disorders of glucose metabolism have emerged as an important issue in the care of this population. Multiple mechanisms, both specific and nonspecific to HIV, underlie a significant prevalence. Although best-practice diagnostic testing remains unclear, the risks associated with diabetes in the setting of HIV are well characterized, ranging from organ-specific damage to socioeconomic decline. As population-specific treatment data are limited, current guidelines serve as a basis for ongoing management.
authors.affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, 10 Center Drive, Bethesda, MD 20892, USA. Electronic address: hadiganc@niaid.nih.gov.
authors.forename: Colleen
authors.initials: C
authors.lastname: Hadigan
authors.affiliation: Laboratory of Immunoregulation, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, 5705 Industry Lane, Frederick, MD 21702, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Kattakuzhy
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D015658:HIV Infections / Q000453:epidemiology* / Q000378:metabolism / Q000628:therapy; D015497:HIV-1 / Q000502:physiology; D006801:Humans
keywords: Cardiovascular disease; Combination antiretroviral therapy; Diabetes; Disorders of glucose metabolism; Human immunodeficiency virus